Gastritis Treatment Market Size was valued at USD 0.08 Billion in 2023. The Gastritis Treatment industry is projected to grow from USD 0.14 Billion in 2024 to USD 0.49 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.63% during the forecast period (2024 - 2032). Gastritis is characterized by a set of conditions that cause inflammation or irritation of the lining of the stomach, for a short or long time. Upper abdominal pain or discomfort is the most common symptom of Gastritis. Gastritis has been broadly categorized into three segments, namely, acute gastritis, chronic gastritis, and erosion of metaplasia or atrophic gastritis. The market for gastritis treatment is expanding worldwide due to drivers such as increasing occurrence of acute and chronic gastritis, advances in the area of medical technologies, increasing fast food chains worldwide, massive adoption of a sedentary lifestyle, and advancement in endoscopy devices that increased the accuracy of diagnosis. Moreover, chronic gastritis patients, rely on acidity reducing medicines for a lifetime, thus fueling the market demand which in turn would boost up the market growth. However, unaffordability and lack of advanced medical device technology in middle-income countries are likely to hamper the gastritis treatment market growth.
Daewoong Pharmaceutical (CEO Jeon Seng-ho, Lee Chang-jae) announced that the company has decided to officially launch ‘Fuxuprazan’ in the Philippines on August 27th, 2023. In just a year after launching Fexuprazan, this is the first successful expansion of Daewoong Pharmaceutical worldwide. From 2008 to the period of thirteen years, Daewoong Pharmaceuticals developed an in-house medicine, Fexuprazan with their own technology covered by patents which has five major advantages such as a quick action and marked symptom improvement, excellent night time relief, low side effect incidence and easy administration.
Phathom Pharmaceuticals Inc., a biopharmaceutical company which develops and commercializes new remedies for GI (gastrointestinal) diseases, today reported that U.S. Food and Drug Administration (FDA) approved VOQUEZNA® (vonoprazan) tablets 10mg and 20mg for healing all grades of Erosive Esophagitis also known as Erosive GERD (gastroesophageal reflux disease), maintenance healing all grades of Erosive GERD as well as heartburn relief associated with Erosive GERD. It is called erosive GERD or erosive esophagitis or erosive acid reflux disease making it unique among other forms affecting about twenty million Americans alone. Those patients who have not received appropriate anti-reflux therapy may suffer from severe conditions like Barrett’s esophagus where changes in esophageal tissue can lead to cancer.
South Korean bio-health firm HK inno.N Corporation’s new gastroesophageal reflux disease drug ‘K-CAB’ has been officially launched in Indonesia – the largest market in Southeast Asia. HK inno.N announced on Monday that it has launched the GERD drug K-CAB (generic name: Tegoprazan) in Indonesia. This Indonesian version of the product is called ‘Teza’, while its distribution and marketing will be looked after by the leading South-East Asian pharmaceutical company, Kalbe. Kalbe, a partner firm, specializes in gastrointestinal disease with $261m sales as of 2022 making it the topmost pharmaceutical sales organization countrywide in Indonesia.
Market Players
The gastritis treatment market is segmented on the basis of diagnosis, treatment type, drug distribution channel, and end-users.
Considering the diagnosis, the market is segmented into blood test, endoscopy, x-ray of the upper digestive system and others.
By treatment type, the gastritis treatment market is segmented into acid-blocking medicines, antibiotics, antacids, and histamine blockers.
With reference to the drug distribution channel, the gastritis treatment market is segmented into retail pharmacy, online pharmacy, and hospital pharmacy.
On account of end-users, the gastritis treatment market is segmented hospitals & clinics and others.
Based on region the market is segmented into Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
The Americas is going to account for the largest share for gastritis treatment market. Drivers such as widespread of fast food chains in this region along with the increasing sedentary life culture which in turn contributes to increasing patient pool of gastritis and rising geriatric population are likely to enhance the growth of gastritis treatment market. Moreover, rising alcohol abuse, the presence of prominent key players is likely to spur the market growth. For instance, According to a published survey, approximately 1 in 100 is a victim of gastritis in the US. Thus, this increasing patient pool will enhance the market growth during the forecasted period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of gastritis treatment market in the American region. Furthermore, according to CMS (Centers for Medicare and Medicaid Services) US health care spending increased 4.3 percent to reach USD 3.3 trillion per person in 2016. Thus, the increasing per capita income of individuals, as well as rising healthcare spending, will aid up the market growth of the Americas.
Europe is the second market leader and holds a healthy share in the gastritis treatment market. The European market is expected to exhibit a sturdy growth rate during the forecast period owing to the availability of advanced treatment facilities, established healthcare infrastructure along with the presence of a flourishing medical device market which helps in efficient and accurate diagnosis. Furthermore, due to the increasing number of lactose-intolerant issues, vulnerability to falling prey of gastritis is more likely to lead to an increasing number of gastritis sufferers. Thus, fueling the market growth during the forecast period.
Asia-Pacific is expected to be the fastest emerging market owing to increasing government initiatives for healthcare reform, increasing adaption of a sedentary lifestyle, and increasing prevalence of gastritis. Moreover, the prevalence of multifocal atrophic gastritis and gastric adenocarcinomas is high in these regions. Furthermore, the presence of renowned domestic pharmaceutical players, as well as the increasing healthcare spending per capita, is going to accelerate the market growth during the forecast period.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. With an increasing number of gastrointestinal disorders region in this region, many key players are willing to set up their research and development centers to find a cure for these diseases. Moreover, the government is aiming at improving the healthcare infrastructure. Thus, a steady growth rate might be seen during the forecast period.
Gastritis Treatment Market, by Diagnosis
Gastritis Treatment Market, by Treatment type
Gastritis Treatment Market, by Drug Distribution Channel
Gastritis Treatment Market, by End-User
Gastritis treatment Market, By Region
North America
South America
Europe
Asia-Pacific
Middle East and Africa
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | Â 0.49 Billion |
| Â Â CAGR | Â Â 2024-2032: 4.63% CAGR |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2024-2032 |
| Â Â Historical Data | Â Â 2018 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Diagnosis, Treatment, Drug Distribution, End User |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
|   Key Vendors |   Abbott Laboratories, AstraZeneca PLC, Novartis AG, Microbiotix, Inc, Reddy’s Laboratories, Lupin Ltd, Perrigo Pharmaceutical, Cipla Inc., Pfizer Inc., SUN Pharmaceuticals Industries limited |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Increasing occurrence of acute and chronic gastritis· Advances in the area of medical technologies· Increasing fast food chains worldwide· Massive adoption of a sedentary lifestyle· Advancement in endoscopy devices that increased the accuracy of diagnosis |
Gastritis Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Americas is expected to lead the Gastritis Treatment Market.
Rising prevalence of chronic gastritis and advancement in endoscopy devices are adding market growth.
Hospitals and clinics are the end users of gastritis treatment.
Top players in the Gastritis Treatment Market include SUN Pharmaceuticals Industries Limited, Pfizer Inc., Cipla Inc., Perrigo Pharmaceutical, Lupin Ltd, Dr. Reddy’s Laboratories, Microbiotix, Inc, Novartis AG, AstraZeneca PLC, and Abbott Laboratories.
Different strategies used by market players to create a dominance in the Gastritis Treatment Market include acquisitions, product launches, partnerships, and collaborations.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
